Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
In this comparative effectiveness study, differential censoring explained the inconsistent results reported in the evaluated trials. The term perceived-inferiority censoring is suggested to describe a phenomenon wherein better-performing patients are aware of their treatment and drop out to pursue alternative therapeutic options; it is possible that this occurred in the open-label KEYNOTE-361 and CheckMate901 trials. Such censoring confounds randomization and interpretation of clinical trials, since a larger experimental group is compared with a selected group of controls with poorer prognosis.
Authors
- Noa Zimhony‐Nissim
- Daniel A. Goldstein (ORCID: https://orcid.org/0000-0002-8082-9622)
- Eli Rosenbaum
- Victoria Neiman
- Bishal Gyawali (ORCID: https://orcid.org/0000-0001-7444-8594)
- Gal Markel (ORCID: https://orcid.org/0000-0003-4835-891X)
- Avital Bareket‐Samish (ORCID: https://orcid.org/0000-0002-4849-7891)
- Nathan I. Cherny (ORCID: https://orcid.org/0000-0003-1976-8952)
- Ian F. Tannock (ORCID: https://orcid.org/0000-0002-2636-7041)
- Jonathan Ofer (ORCID: https://orcid.org/0000-0003-4866-0828)
- Tomer Meirson (ORCID: https://orcid.org/0000-0002-5011-5477)
Institutions
- Tel Aviv University (IL)
- Queen's University (CA)
- Rabin Medical Center (IL)
- Shaare Zedek Medical Center (IL)
- Princess Margaret Cancer Centre (CA)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.55630
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02